ArticlePharmacoEconomics2017
Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix
Article in PharmacoEconomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Economic effectiveness of pharmacogenomics-guided prescribing for psychiatric disorders: a systematic review and meta-analysis.The pharmacogenomics journal · 2026Pooled it
- Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review.Clinical pharmacology and therapeutics · 2022Pooled it
- Economic evaluation in psychiatric pharmacogenomics: a systematic review.The pharmacogenomics journal · 2021Pooled it
- Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.Ontario health technology assessment series · 2021Pooled it
- Analyzing pharmacogenetics cost effectiveness and savings across common health conditions in the United States.The pharmacogenomics journal · 2025Review
- A Canadian Simulation Model for Major Depressive Disorder: Study Protocol.PharmacoEconomics - open · 2024Review
- Cost-effectiveness analysis of genotype-guided optimization of major depression treatment in Qatar.Journal of pharmaceutical policy and practice · 2024Article
- Cost-effectiveness of pharmacogenomic-guided treatment for major depression.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023Article
- Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis.Translational psychiatry · 2021Review
- Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children's Genomic Medicine Consortium.The pharmacogenomics journal · 2021Review
- A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe response to therapeutics varies widely in patients with depression and anxiety, making selection of an optimal treatment choice challenging. IDgenetix
objectiveThe objective of this study was to estimate the cost effectiveness of implementing a novel pharmacogenomic test (IDgenetix
methodsWe developed a discrete event simulation to compare clinical events, quality-adjusted life-years, and costs of the two treatment strategies. Target patients had a Hamilton Rating Scale for Depression Score ≥ 20 and/or a Hamilton Rating Scale for Anxiety score ≥ 18 at baseline. Remission, response, and no response were simulated based on the observed rates in the IDgenetix
resultsThe model predicted cumulative remission rates of 78 and 66% in IDgenetix
conclusionUsing the IDgenetix
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.